摘要
随着新型药物研究的进展,多发性骨髓瘤患者生存期延长,发生二次肿瘤概率增加,而多发性骨髓瘤合并第二肿瘤在临床工作中却少见报道。因此,多发性骨髓瘤治疗过程中出现一些原发病无法解释的临床症状以及异常检验指标等,应高度警惕第二肿瘤的发生。因此,治疗多发性骨髓瘤过程中出现一些原发病无法解释的临床症状以及异常检验指标等,应高度警惕第二肿瘤的发生。多发性骨髓瘤合并肝癌临床症状较为隐匿,容易漏诊。现报道两例某院收治多发性骨髓瘤合并肝癌患者,结合文献复习,由此来提高多发性骨髓瘤合并第二肿瘤的认识。
With the progress of development in novel drugs,patients with multiple myeloma have prolonged survival and increased chance of secondary malignancy(SM).However,multiple myeloma combined with secondary malignancy has been rarely reported in clinical practice.Secondary malignancy should be considered when some clinical symptoms and abnormal test parameters cannot be explained by the primary disease during the treatment of multiple myeloma.The clinical symptoms of multiple myeloma combined with hepatoma are relatively insidious and easy to be misdiagnosed.Here we report two cases of multiple myeloma combined with hepatoma,and review the literature to improve the understanding of multiple myeloma combined with secondary malignancy.
作者
王丽静
朱敏
童周欣
陈丽
商安芳
郭静明
蔡惠丽
WANG Li-jing;ZHU Min;TONG Zhou-xin;CHEN Li;SHANG An-fang;GUO Jing-ming;CAI Hui-li(Department of Hematology,the First College of Clincal Medical Science,China Three Gorges University(Yichang Central People's Hospital),Yichang 443000,Hubei,CHINA;Department of Internal Medicine,Changyang Tujia Autonomous County Hospital of Traditional Chinese Medicine,Yichang 443500,Hubei,CHINA;Department of Internal Medicine,Affiliated Hospital of Hubei University of Medicine(Xiangyang First People's Hospital),Xiangyang 441000,Hubei,CHINA)
出处
《海南医学》
CAS
2023年第14期2079-2081,共3页
Hainan Medical Journal
基金
湖北省自然科学基金青年项目(编号:2017CFB334)。
关键词
多发性骨髓瘤
肝癌
第二肿瘤
来那度胺
环磷酰胺
化疗
Multiple myeloma
Liver cancer
Secondary malignancy
Lenalidomide
Cyclophosphamide
Chemotherapy
